Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressiv...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Witzig, Thomas E., Tang, Hui, Micallef, Ivana N. M., Ansell, Stephen M., Link, Brian K., Inwards, David J., Porrata, Luis F., Johnston, Patrick B., Colgan, Joseph P., Markovic, Svetomir N., Nowakowski, Grzegorz S., Thompson, Carrie A., Allmer, Cristine, Maurer, Matthew J., Gupta, Mamta, Weiner, George, Hohl, Ray, Kurtin, Paul J., Ding, Husheng, Loegering, David, Schneider, Paula, Peterson, Kevin, Habermann, Thomas M., Kaufmann, Scott H.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2011
الموضوعات:
Clinical Trials and Observations
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208296/
https://ncbi.nlm.nih.gov/pubmed/21725056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-334904
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة